Epigenetics in the biology and treatment of multiple myeloma

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

There is a critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A variety of both genetic and epigenetic abnormalities may be present in MM, the latter including DNA and histone methylation and histone deacetylation, and are thought to contribute to the pathogenesis of the disease. For example,global methylation analysis in MM has identified inactivated tumour suppressor genes that are prognostically important. Through their ability to acetylate histones and cytoplasmic proteins, histone deacetylases (HDAC) influence a wide variety of cellular functions, such as proliferation, differentiation and apoptosis. Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor–monoclonal antibody combinations are also being explored. The potential of HDAC inhibitors to improve outcome for patients with MM is evident but a greater understanding of their anti-tumour effects is needed.
Original languageEnglish
Pages (from-to)96-102
Number of pages7
JournalEuropean Oncology & Haematology
Volume12
Issue number2
DOIs
Publication statusPublished - 2016

Keywords

  • Combination strategies
  • DNA methylation
  • Epigenetics
  • Histone deacetylases inhibitors
  • Histone modifications
  • Multiple myeloma (MM)
  • Panobinostat
  • Ricolinostat

Cite this

@article{d5a11253245c4b89b124170b0d46ea28,
title = "Epigenetics in the biology and treatment of multiple myeloma",
abstract = "There is a critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A variety of both genetic and epigenetic abnormalities may be present in MM, the latter including DNA and histone methylation and histone deacetylation, and are thought to contribute to the pathogenesis of the disease. For example,global methylation analysis in MM has identified inactivated tumour suppressor genes that are prognostically important. Through their ability to acetylate histones and cytoplasmic proteins, histone deacetylases (HDAC) influence a wide variety of cellular functions, such as proliferation, differentiation and apoptosis. Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor–monoclonal antibody combinations are also being explored. The potential of HDAC inhibitors to improve outcome for patients with MM is evident but a greater understanding of their anti-tumour effects is needed.",
keywords = "Combination strategies, DNA methylation, Epigenetics, Histone deacetylases inhibitors, Histone modifications, Multiple myeloma (MM), Panobinostat, Ricolinostat",
author = "Andrew Spencer and Sridurga Mithraprabhu",
year = "2016",
doi = "10.17925/EOH.2016.12.02.96",
language = "English",
volume = "12",
pages = "96--102",
journal = "European Oncology & Haematology",
issn = "2045-5275",
number = "2",

}

Epigenetics in the biology and treatment of multiple myeloma. / Spencer, Andrew; Mithraprabhu, Sridurga.

In: European Oncology & Haematology, Vol. 12, No. 2, 2016, p. 96-102.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Epigenetics in the biology and treatment of multiple myeloma

AU - Spencer, Andrew

AU - Mithraprabhu, Sridurga

PY - 2016

Y1 - 2016

N2 - There is a critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A variety of both genetic and epigenetic abnormalities may be present in MM, the latter including DNA and histone methylation and histone deacetylation, and are thought to contribute to the pathogenesis of the disease. For example,global methylation analysis in MM has identified inactivated tumour suppressor genes that are prognostically important. Through their ability to acetylate histones and cytoplasmic proteins, histone deacetylases (HDAC) influence a wide variety of cellular functions, such as proliferation, differentiation and apoptosis. Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor–monoclonal antibody combinations are also being explored. The potential of HDAC inhibitors to improve outcome for patients with MM is evident but a greater understanding of their anti-tumour effects is needed.

AB - There is a critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A variety of both genetic and epigenetic abnormalities may be present in MM, the latter including DNA and histone methylation and histone deacetylation, and are thought to contribute to the pathogenesis of the disease. For example,global methylation analysis in MM has identified inactivated tumour suppressor genes that are prognostically important. Through their ability to acetylate histones and cytoplasmic proteins, histone deacetylases (HDAC) influence a wide variety of cellular functions, such as proliferation, differentiation and apoptosis. Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor–monoclonal antibody combinations are also being explored. The potential of HDAC inhibitors to improve outcome for patients with MM is evident but a greater understanding of their anti-tumour effects is needed.

KW - Combination strategies

KW - DNA methylation

KW - Epigenetics

KW - Histone deacetylases inhibitors

KW - Histone modifications

KW - Multiple myeloma (MM)

KW - Panobinostat

KW - Ricolinostat

UR - http://www.scopus.com/inward/record.url?scp=85006379779&partnerID=8YFLogxK

U2 - 10.17925/EOH.2016.12.02.96

DO - 10.17925/EOH.2016.12.02.96

M3 - Review Article

VL - 12

SP - 96

EP - 102

JO - European Oncology & Haematology

JF - European Oncology & Haematology

SN - 2045-5275

IS - 2

ER -